Improved survival with vemurafenib in melanoma with BRAF V600E mutation by Chapman Paul B, Hauschild Axel, Robert Caroline, Haanen John B, Ascierto Paolo, Larkin James, Dummer Reinhard, Garbe Claus, Testori Alessandro, Maio Michele, Hogg David, Lorigan Paul, Lebbe Celeste, Jouary Thomas, Schadendorf Dirk, Ribas Antoni, O'Day Steven J, Sosman Jeffrey A, Kirkwood John M, Eggermont Alexander M M, Dreno Brigitte, Nolop Keith, Li Jiang, Nelson Betty, Hou Jeannie, Lee Richard J, Flaherty Keith T, McArthur Grant A, BRIM-3 Study Group in The New England journal of medicine (2011).

[PMID: 21639808] PubMed


Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.